menu
    • menu
    [{"orgOrder":0,"company":"NovaLead Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"INDIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-1 adrenergic receptor | Beta-2 adrenergic receptor","graph1":"Podiatry","graph2":"Phase III","graph3":"NovaLead Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"NovaLead Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NovaLead Pharma \/ Undisclosed"},{"orgOrder":0,"company":"NovaLead Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"INDIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-1 adrenergic receptor | Beta-2 adrenergic receptor","graph1":"Podiatry","graph2":"Phase III","graph3":"NovaLead Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovaLead Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NovaLead Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Central Hospital, Nancy, France","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Central Hospital, Nancy, France","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Central Hospital, Nancy, France \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Central Hospital, Nancy, France \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Health Network, Toronto \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University Health Network, Toronto \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Duke University","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Undisclosed","graph2":"Phase III","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Duke University \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Duke University \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Intermountain Health","sponsor":"Beth Israel Deaconess Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Intermountain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intermountain Health \/ Beth Israel Deaconess Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Intermountain Health \/ Beth Israel Deaconess Medical Center"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Esmolol Hydrochloride

    Menu

    Esmolol Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NovaLead Pharma

                            India arrow
                            CTAD25
                            Not Confirmed

                            NovaLead Pharma

                            India arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Podiatry

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Study to Evaluate the Safety and Efficacy of Galnobax® in Treating Diabetic Foot Ulcers

                            Details : Esmolol HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 26, 2019

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            CTAD25
                            Not Confirmed

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)

                            Details : Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhagic Stroke.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 15, 2018

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Intermountain Health

                            Country arrow
                            CTAD25
                            Not Confirmed

                            Intermountain Health

                            Country arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Beth Israel Deaconess Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia

                            Details : Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Shock, Septic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 22, 2016

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Beth Israel Deaconess Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Assistance Publique – Hôpitaux de Paris

                            Country arrow
                            CTAD25
                            Not Confirmed

                            Assistance Publique – Hôpitaux de Paris

                            Country arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Baxter Healthcare Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of S...

                            Details : Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Shock, Septic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 22, 2014

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Baxter Healthcare Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Central Hospital, Nancy, France

                            Country arrow
                            CTAD25
                            Not Confirmed

                            Central Hospital, Nancy, France

                            Country arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Baxter Healthcare Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Esmolol Effects on Heart and Inflammation in Septic Shock

                            Details : Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Shock, Septic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 21, 2014

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Baxter Healthcare Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            University Health Network, Toronto

                            Country arrow
                            CTAD25
                            Not Confirmed

                            University Health Network, Toronto

                            Country arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Baxter Healthcare Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol

                            Details : Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Vascular Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 28, 2011

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Baxter Healthcare Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Duke University

                            Country arrow
                            CTAD25
                            Not Confirmed

                            Duke University

                            Country arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Baxter Healthcare Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Esmolol for Treatment of Perioperative Tachycardia

                            Details : Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 24, 2010

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Baxter Healthcare Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            NovaLead Pharma

                            India arrow
                            CTAD25
                            Not Confirmed

                            NovaLead Pharma

                            India arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers

                            Details : Esmolol HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 30, 2010

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth